Drug Trial Radar · NCT07027020
Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction
Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 15, 2026
Primary completion
Jan 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Central Hospital, Nancy, FranceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France; FARCO PHARMA
- First posted
- Jun 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Malformation of the lumbosacral region (spina bifida) affects the innervation of the bladder in children. The usual evolution leads to a neurological bladder with small capacity, poor compliancy and overactivity, exposing to incontinence and obstruction to the evacuation of urine. It is responsible for renal failure requiring dialysis and transplantation. Current therapeutics aim to evacuate urine and reduce intravesical pressure. It gradually combines 1) intermittent catheterization, 2) anticholinergics, 3) botulinum toxin (Botox®) injection into the detrusor (bladder muscle) by cystoscopy and 4) surgery (vesicostomy, Bricker, enterocystoplasty). Oxybutynin relaxes the detrusor, improves continence and reduces intravesical pressure. It is usually administered per os, but there are contraindications (glaucoma, myasthenia), side effects (constipation, dry mouth). It can be difficult to swallow for children, and drug resistance may develop. It can lead to ineffective treatment requiring therapeutic escalation. The next step, intradetrusor Botox® injection, is invasive (cystoscopy), has a limited duration of action (6 months) and must be performed under general anesthesia in children. Surgical treatments are effective but irreversible and responsible for morbidity and mortality. A randomized study was performed demonstrating the efficacy of intravesical oxybutynin compared to oral administration in adult patients. This study found a significant increase in bladder capacity and a significant decrease in side effects in the intravesical oxybutynin group. Due to the relative difficulties of intravesical oxybutynin delivery (preparation, cost) and the more invasive nature, it is not used as an alternative to oral oxybutynin. The hypothesis of this study is that this treatment may have a legitimate place in the treatment of neurogenic bladder in patients with failure of anticholinergic treatment before a therapeutic escalation requiring an invasive procedure (Botox®, enterocystoplasty) especially in children for whom repeated general anesthesia for Botox® injection may interfere with brain development. In this way, the investigators aim to extend the time to therapeutic escalation in the pediatric population. The main objective of the trial is to compare the efficacy on maximal bladder capacity of intravesical oxybutynin instillation versus placebo in the treatment of children with overactive neurogenic bladder (spina bifida), performing intermittent catheterization, for whom oral anticholinergic treatment is ineffective or poorly tolerated.
Conditions
- Spina Bifida
Interventions
Oxybutynin HydrochlorideDrug
Pharmaceutical form: solution. Route of administration: Intravesical. Medicinal product unique ID: PRD8074745. EU active substance code: SUB03581MIG.
PlaceboDrug
Pharmaceutical form: solution. Route of administration: Intravesical.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evolution of maximal bladder capacity at 4 weeks of treatment (end of follow-up)Time frame: 4 weeks
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier Universitaire de Besançon
Besançon, France · Not yet recruiting
Centre Hospitalier Universitaire De Bordeaux
Bordeaux, France · Not yet recruiting
Centre Hospitalier Régional Et Universitaire De Brest
Brest, France · Not yet recruiting
Centre Hospitalier Universitaire De Caen Normandie
Caen, France · Not yet recruiting
Centre Hospitalier Universitaire de Clermont-Ferrand
Clermont-Ferrand, France · Not yet recruiting
Centre Hospitalier De Colmar
Colmar, France · Not yet recruiting
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, France · Not yet recruiting
Centre Hospitalier Universitaire de Lille
Lille, France · Not yet recruiting
Centre Hospitalier Et Universitaire De Limoges
Limoges, France · Not yet recruiting
Centre Hospitalier Régional De Marseille
Marseille, France · Not yet recruiting
Fondation Lenval Nice
Nice, France · Not yet recruiting
Hôpital Necker Enfants Malades
Paris, France · Not yet recruiting
Hôpital Trousseau (chirurgie viscérale pédiatrique et néonatale)
Paris, France · Not yet recruiting
Hôpital Trousseau (médecine physique et de réadaptation pédiatrique)
Paris, France · Not yet recruiting
Centre Hospitalier Universitaire de Poitiers
Poitiers, France · Not yet recruiting
Centre Hospitalier Universitaire de Rennes
Rennes, France · Not yet recruiting
Centre Hospitalier Universitaire De Saint Etienne
Saint-Etienne, France · Not yet recruiting
Les Hopitaux Universitaires De Strasbourg
Strasbourg, France · Not yet recruiting
Centre Hospitalier Régional Et Universitaire de Nancy
Vandœuvre-lès-Nancy, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.